The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases. Through the Foundation, Sanofi extends its commitment to improving people's lives beyond healthcare by supporting younger generations facing some of today's most pressing health, climate, and humanitarian challenges.

Bristol Myers Squibb (NYSE: BMY), a global leader in oncology, announced the evolution of Standing in the Gaap, a long-running program designed to help address persistent gaps in care for people living with multiple myeloma (MM) in medically underserved communities. Building on a decade of sustained commitment, BMS is reinforcing its focus on equitable access to multiple myeloma education, resources, and community-driven solutions by expanding the program to reach more patients and care partners.

Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform.

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder.

Abbott (NYSE: ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players aged 18-19 across the United States to sign up for the chance to take part in a once-in-a-lifetime development experience in Madrid. Selected participants will train with Real Madrid's world‑renowned coaches at the club's facilities and enjoy unique opportunities, including attending a Real Madrid match at the Bernabéu Stadium and meeting club legends.

Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥ 75% reduction in the Eczema Area and Severity Index) at Week 16, compared to placebo.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).